Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834431 · ClinicalTrials.gov registry record · Phase 1
Famciclovir 500 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00834431: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00834431 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00834431, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under fasting conditions.
Interventions
- DRUG Famciclovir 500 mg Tablets
- DRUG Famvir® 500 mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-08 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00834431
The ClinicalTrials.gov registry entry for NCT00834431 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Famciclovir 500 mg Tablets is the first listed.
NCT00834431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00834431 about?
NCT00834431 is a clinical study titled "Famciclovir 500 mg Tablets Under Fasting Conditions". The objective of this study is to compare the relative bioavailability of famciclovir 500 mg tablets (Novopharm Limited) with that of FAMVIR® 500 mg tablets (Novartis) in healthy adult subjects under fasting conditions.
What is the current status of trial NCT00834431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-08. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00834431?
The interventions under investigation include: Famciclovir 500 mg Tablets (DRUG), Famvir® 500 mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00834431?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.